PolTREG initiates preclinical study of CAR-Treg cells for neuroinflammatory diseases, including multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS).

A new study confirms that perceived stress directly triggers psoriasis relapse, providing the first scientific validation of this long-suspected connection.

Mike Peters, frontman of The Alarm, achieved remission from aggressive Richter's syndrome after participating in an NHS drug trial at The Christie in Manchester.

Bob Ehlers, diagnosed with mild cognitive impairment from Alzheimer's, participates in a clinical trial at Banner Alzheimer's Institute to combat disease progression.

Allogene Therapeutics stopped enrolling patients in its Phase 1 trial of cemacabtagene ansegedleucel (cema-cel) for relapsed or refractory chronic lymphocytic leukemia (CLL).

Tovorafenib (Ojemda) demonstrates durable responses in pediatric patients with BRAF-altered relapsed/refractory low-grade glioma during drug holidays in the FIREFLY-1 trial.

Nomlabofusp treatment demonstrates modification of gene expression and lipid profiles, alongside increased frataxin (FXN) levels in Friedreich's ataxia (FA) patients.

Plasma p-tau217-based tests are seeking regulatory approval in the U.S. and Europe as fully automated in vitro diagnostics for Alzheimer's disease.

Cassava Sciences appointed Freda Nassif as Chief Commercial Officer to spearhead commercial strategies for simufilam, their Alzheimer's drug candidate.

Gildeuretinol (ALK-001) receives Rare Pediatric Disease and Fast Track designations from the FDA, highlighting the urgent need for Stargardt disease treatments.

CRISPR Therapeutics' stock has declined despite the FDA and EU approvals of Casgevy for sickle cell disease and transfusion-dependent beta thalassemia.

Jacobio Pharmaceuticals has commenced a clinical trial for a new cancer drug, marking a significant step in their oncology program.

The FDA has approved BridgeBio's Attruby (acoramidis) for adults with transthyretin amyloid cardiomyopathy (ATTR-CM), a rare and life-threatening heart condition.

SynAct Pharma received EU approval for its Phase 2b ADVANCE study of resomelagon (AP1189) in newly diagnosed severe rheumatoid arthritis (RA) patients.

Trikafta's expanded coverage marks a significant advancement in treating cystic fibrosis, offering hope for improved outcomes for a broader range of patients.

Global clinical trials for cell and gene therapies have expanded by 32.5% between 2019 and 2023, indicating rapid growth in the field.

SELLAS Life Sciences reports that SLS009, a CDK9 inhibitor, demonstrates high efficacy in preclinical models of solid cancers with ASXL1 mutations.

Dr. Daniel Gibbs, a neurologist with early-stage Alzheimer's, shares his experiences and strategies for slowing disease progression, including diet and exercise.

Sunshine Biopharma's K1.1 mRNA demonstrated dose-dependent anti-proliferative activity against human hepatocellular carcinoma (HCC) cells in vitro.

Dermata Therapeutics' DMT310, a novel topical product, is in Phase III trials for moderate-to-severe acne, offering a once-weekly treatment option.